In this issue of EMBO Molecular Medicine, Hoppe et al present RAD51 expression as a biomarker of platinum resistance in high‐grade serous ovarian cancer (HGSOC) patients (Hoppe et al, 2021). Here, RAD51 is linked to ovarian serous adenocarcinoma.